Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Recent & Breaking News (NDAQ:MESO)

Mesoblast Completes Private Placement

GlobeNewswire April 25, 2023

FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing

GlobeNewswire March 21, 2023

FDA Accepts Mesoblast's Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023

GlobeNewswire March 7, 2023

Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022

GlobeNewswire February 27, 2023

DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)

GlobeNewswire February 27, 2023

Mesoblast Financial Results and Corporate Update Webcast

GlobeNewswire February 26, 2023

Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy

GlobeNewswire February 16, 2023

FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain

GlobeNewswire February 8, 2023

Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

GlobeNewswire January 31, 2023

Appendix 4C Quarterly Activity Report

GlobeNewswire January 31, 2023

Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility

GlobeNewswire December 22, 2022

Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

GlobeNewswire November 22, 2022

Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022

GlobeNewswire November 22, 2022

Mesoblast Financial Results and Corporate Update Webcast

GlobeNewswire November 21, 2022

Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022

GlobeNewswire October 30, 2022

Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

GlobeNewswire October 2, 2022

Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022

GlobeNewswire August 30, 2022

Mesoblast Corporate Update and Financial Results Webcast

GlobeNewswire August 29, 2022

Jane Bell Joins Mesoblast Board

GlobeNewswire August 18, 2022

Appendix 4C Quarterly Activity Report

GlobeNewswire July 29, 2022